Clinical Pharmacokinetics

, Volume 32, Issue 5, pp 368–381 | Cite as

Pharmacokinetic Studies with Recombinant Cytokines

Scientific Issues and Practical Considerations
  • Stephen C. Piscitelli
  • William G. Reiss
  • William D. Figg
  • William P. Petros
Review Article Drug Disposition

Summary

Advances in molecular biology and recombinant DNA technology have led to the development of cytokines as therapeutic agents for a variety of disease states. The pharmacokinetic analysis of cytokines involves the understanding of analytical methods capable of detecting these agents in biological fluids and recognition of several factors which may have an impact on the cytokine concentration-time curves.

Enzyme-linked immunosorbent assays (ELISA) have become the most common method of detection and commercial kits are available for a wide variety of cytokines. Monoclonal antibody products are sensitive, have minimal crossreactivity and are relatively inexpensive when compared with high performance liquid chromatography (HPLC). However, the primary limitation of these assays is their inability to measure biologically active protein. Conversely, bioassays do measure a biological event (i.e. proliferation or cytotoxicity) but are generally not used for cytokine analysis because of their high cost, long assay completion time, lack of specificity, poor sensitivity and influence of environmental conditions on the outcome.

The pharmacokinetic profile of recombinant cytokines is influenced by a number of variables: endogenous production, circulating soluble receptors and cell-associated receptors, immunocompetence and antibody production against the cytokine all may influence the disposition of the agent. Thus, pharmacokinetic modelling of cytokines may involve complex models capable of characterising these nonlinear processes and resulting effects.

The route of administration is an important variable since cytokines administered by subcutaneous injection may be partially metabolised by proteases present in the subcutaneous tissue. Other methods to simplify cytokine delivery are being actively investigated and include formulations for inhalation, topical and oral administration. A variety of cytokines (including interferon-α, interleukin-6 and tumour necrosis factor) are capable of inhibiting cytochrome P450 hepatic enzymes and, therefore, possess the potential to cause drug-cytokine interactions. Inhibition has been demonstrated in several in vitro systems and animal models, although clinical data are currently limited.

An increased understanding of the many factors which can alter the analysis and pharmacokinetics of cytokines is essential to the design of optimal dosage regimens.

Keywords

Adis International Limited Stem Cell Factor Cytokine Concentration Soluble Receptor Clofibric Acid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thorpe R, Wadhwa M, Bird CR, et al. Detection and measurement of cytokines. Blood Rev 1992; 6: 133–48PubMedCrossRefGoogle Scholar
  2. 2.
    Yamada T, Fujishima A, Kawahara K, et al. Importance of disulfide linkage for constructing the biologically active human interleukin-2. Arch Biochem Biophys 1987; 257: 194–9PubMedCrossRefGoogle Scholar
  3. 3.
    Foss FM, Borkowski TA, Gilliom M, et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994;84: 1765–74PubMedGoogle Scholar
  4. 4.
    Cannon JG, van der Meer JW, Kwiatkowski D, et al. Interleukin-1-beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 1988; 7: 457–67PubMedGoogle Scholar
  5. 5.
    Rossio JL, Rager HC, Goundry CS, et al. Cytokine testing in clinical trial monitoring. In: Rose NR, DeMarcario EC, Fahey JL, et al., editors. Manual of clinical laboratory immunology. 4th ed. Washington, DC: American Society for Microbiology, 1992:942–7Google Scholar
  6. 6.
    Cairo MS, Suen Y, Sender L, et al. Circulating granulocyte colony-stimulating factor levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992; 79: 1869–73PubMedGoogle Scholar
  7. 7.
    Huanmura T, Motoyoshi K, Yosha K, et al. Quantification and identification of human monocytic colony-stimulating factor in human serum by enzyme-linked immunosorbent assay. Blood 1988; 72: 886–92Google Scholar
  8. 8.
    Layton JE, Hockman H, Sheridan WP, et al. Evidence for a novel in vivo control mechanism for granulopoiesis: mature cell-regulated control for regulatory growth factor. Blood 1989; 74: 1303–7PubMedGoogle Scholar
  9. 9.
    Petros WP, Rabinowitz J, Stuart AR, et al. Disposition of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving high-dose chemotherapy and autologous bone marrow support. Blood 1992; 80: 1135–40PubMedGoogle Scholar
  10. 10.
    McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76: 1718–22PubMedGoogle Scholar
  11. 11.
    Bukowski RM, Budd GT, Gibbons JA, et al. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 1994; 12:97–106PubMedGoogle Scholar
  12. 12.
    Bonner JC, Brody AR. Cytokine-binding proteins in the lung. Am J Physiol 1995; 268: L869–78PubMedGoogle Scholar
  13. 13.
    Guillaume T, Sekhavat M, Rubinstein DB, et al. Transcription of genes encoding granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 6 receptors and lack of proliferative response to exogenous cytokines in nonhematopoietic human malignant cell lines. Cancer Res 1993; 53:3139–44PubMedGoogle Scholar
  14. 14.
    Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995; 9: 50–6PubMedGoogle Scholar
  15. 15.
    Miyajima A, Mui ALF, Ogorochi T, et al. Receptors for granulocyte-macrophage colony-stimulating factor, Interleukin-3, and Interleukin-5. Blood 1993; 82: 1960–74PubMedGoogle Scholar
  16. 16.
    Clemens MJ, editor. Cytokines. Oxford: βios Scientific, 1991Google Scholar
  17. 17.
    Cosman D. The hematopoietic receptor superfamily. Cytokine 1993; 5: 95–106PubMedCrossRefGoogle Scholar
  18. 18.
    Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal transduction. Annu Rev Immunol 1992; 10: 295–331PubMedCrossRefGoogle Scholar
  19. 19.
    Dubois CM, Ruscetti FW, Stern EW, et al. Hematopoietic growth factors upregulate the p65 type II interleukin-1 receptor on bone marrow progenitor cells in vitro. Blood 1992; 80: 600–8PubMedGoogle Scholar
  20. 20.
    Jacobsen SEW, Ruscetti FW, Dubois CM, et al. Induction of colony-stimulating factor receptor expression on hematopoietic progenitor cells: proposed mechanism for growth factor synergism. Blood 1992; 89: 678–87Google Scholar
  21. 21.
    Montero-Julian FA, Klein B, Gautherot E, et al. Pharmacokinetic study of anti-interleukin-6 therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 1995; 85: 917–24PubMedGoogle Scholar
  22. 22.
    Heaney ML, Golde DW. Soluble hormone receptors. Blood 1993; 82: 1945–8PubMedGoogle Scholar
  23. 23.
    Engelmann H, Novick D, Wallach D. Tumor necrosis factorbinding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531–6PubMedGoogle Scholar
  24. 24.
    Yasukawa K, Saito T, Fukunaga T, et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem 1990; 108: 673–6PubMedGoogle Scholar
  25. 25.
    Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599–607PubMedCrossRefGoogle Scholar
  26. 26.
    Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of antirecombinant human granulocyte-macrophage colony-stimulating factor (Eschehchia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994; 84: 4078–87PubMedGoogle Scholar
  27. 27.
    Haas R, Gericke G, Witt B, et al. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol 1993; 21: 109–13PubMedGoogle Scholar
  28. 28.
    Petros WP, Rabinowitz J, Stuart AR, et al. Elevated endogenous serum macrophage colony-stimulating factor in the early stage of fungemia following bone marrow transplantation. Exp Hematol 1994; 22: 582–6PubMedGoogle Scholar
  29. 29.
    Serum levels of stem cell factor are increased in asymptomatic human immunodeficiency virus-infected patients and are associated with prolonged survival. Blood 1995; 86: 243–9Google Scholar
  30. 30.
    Wagner DK, Kiwanuka J, Edwards BK, et al. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 1987; 5: 1262–74PubMedGoogle Scholar
  31. 31.
    Beguin Y, Yerna M, Loo M, et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648–53PubMedCrossRefGoogle Scholar
  32. 32.
    Reibnegger G, Krainer M, Herold M, et al. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250–3PubMedGoogle Scholar
  33. 33.
    Kacinski BM, Stanley ER, Carter D, et al. Circulating levels of CSF-I a lymphohematopoietic cytokine may be a useful marker of disease status in patients with malignant ovarian neoplasms. Int J Radiat Oncol Biol Phys 1989; 17: 159–64PubMedCrossRefGoogle Scholar
  34. 34.
    Porter DL, Goldberg MA. Regulation of erythropoietin production. Exp Heme 1993; 21: 399–404Google Scholar
  35. 35.
    Waage A, Steinshamn S. Cytokine mediators of septic infections in the normal andgranulocytopenic host. Eur J Haematol 1993; 50: 243–9PubMedCrossRefGoogle Scholar
  36. 36.
    Raziuddin S, Sheikha A, Abu-Eshy S, et al. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 1994; 73: 2426–31PubMedCrossRefGoogle Scholar
  37. 37.
    Rabinowitz J, Petros WP, Stuart AR, et al. Characterization of endogenous cytokine concentrations following high-dose chemotherapy with autologous bone marrow support. Blood 1993; 81: 2452–2459PubMedGoogle Scholar
  38. 38.
    Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230–6PubMedCrossRefGoogle Scholar
  39. 39.
    Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–92PubMedCrossRefGoogle Scholar
  40. 40.
    Elkordy M, Crump M, Vredenburgh JJ, et al. A phase I trial of recombinant human interleukin-1b OCT-43) following highdose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant. In pressGoogle Scholar
  41. 41.
    Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76: 1933–40PubMedGoogle Scholar
  42. 42.
    Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990; 323: 86–90PubMedCrossRefGoogle Scholar
  43. 43.
    Macdougall IC, Roberts DE, Coles GA, et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99–115PubMedCrossRefGoogle Scholar
  44. 44.
    Anderson PM, Sorenson MA. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin Pharmacokinet 1994; 27: 19–31PubMedCrossRefGoogle Scholar
  45. 45.
    Bocci V, Carraro F, Zeuli M, et al. The lymphocyte route: VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients. Biotherapy 1993; 6: 73–7PubMedCrossRefGoogle Scholar
  46. 46.
    Rosenfeld CS, Sulecki M, Evans C, et al. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol 1991; 19: 273–77PubMedGoogle Scholar
  47. 47.
    O’Day SJ, Rabinowe SN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma in first remission. Blood 1994; 83: 2707–14PubMedGoogle Scholar
  48. 48.
    Kearns CM, Wang WC, Stute N, et al. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 1993; 123: 471–9PubMedCrossRefGoogle Scholar
  49. 49.
    Porchet HC, Le Cotonnec JY, Loumaye E. Clinical pharamcology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. Fertil Steril 1994; 61: 687–95PubMedGoogle Scholar
  50. 50.
    Jusko WJ, Ko HC. Physiologic indirect response models charcaterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406–19PubMedCrossRefGoogle Scholar
  51. 51.
    Piscitelli SC, Forrest A, Vogel S, et al. A novel PK/PD model for infused interleukin-2 in HIV-infected patients [abstract]. Clin Pharmacol Ther 1996; 60: 162Google Scholar
  52. 52.
    Mannering GJ, Renton KW, el Azhary R, et al. Effects of interferon-inducing agents on hepatic cytochrome P-450 drug metabolizing systems. Ann NY Acad Sci 1980; 350: 314–31PubMedCrossRefGoogle Scholar
  53. 53.
    Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult hepatocytes in primary culture. Mol Pharmacol 1993; 44: 707–15PubMedGoogle Scholar
  54. 54.
    Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 1990; 68: 777–81PubMedCrossRefGoogle Scholar
  55. 55.
    Laio J, Reiss WG. Drug-cytokine interactions: focus on cyclosporine. Pharmacotherapy 1996; 16: 401–8Google Scholar
  56. 56.
    Fukuda Y, Ishida N, Noguchi T, et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P-450 IA1, IA2, IIIA in human hepatoma cells. Biochem Biophys Res Commun 1992; 184: 960–5PubMedCrossRefGoogle Scholar
  57. 57.
    Parmentier JH, Kremers P, Ferrai L, et al. Repression of cytochrome P-450 by cytokines: IL-1 beta counteracts clofibric acid induction of CYP4A in cultured fetal rat hepatocytes. Cell Biol Toxicol 1993; 9: 307–13PubMedCrossRefGoogle Scholar
  58. 58.
    Sakai H, Okamoto T, Kikkawa Y Suppression of hepatic drug metabolism by the interferon inducer, polyribionosinc acid: polyribocitidylic acid. J Pharmacol Exp Ther 1992; 263(1): 381–6PubMedGoogle Scholar
  59. 59.
    Williams JF, William JB, Sinclair JF, et al. Effect of interleukin 6 on phenobarbital induction of cytochrome P-450IIB in cultured rat hepatocytes. Biochem Biophys Res Commun 1991; 178(3): 1049–55PubMedCrossRefGoogle Scholar
  60. 60.
    Barker CW, Fagan JB, Pasco DS. Interleukin-1beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J Biol Chemk 1992; 267: 8050–5Google Scholar
  61. 61.
    Ferrari L, Kremers P, Batt AM, et al. Differential effects of human recombinant interleukin-1beta on cytochrome P-450 dependent activities in cultured fetal rat hepatocytes. Drug Met Disp 1992; 20: 407–12Google Scholar
  62. 62.
    Reiners JJ, Cantu AR, Rupp TA. Coorinate modulation of murine hepatic xanthine oxidase activity and cytochrome P-450 system by interferons. J Interferon Res 1990; 10: 109–18PubMedCrossRefGoogle Scholar
  63. 63.
    Wright K, Morgan ET. Regulation of cytochrome P450IIC12 expression by interleukin-1alpha, interleukin-6, and dexamethasone. Mol Pharmacol 1991; 39: 468–74PubMedGoogle Scholar
  64. 64.
    Craig PI, Mehta I, Murray M, et al. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver. Mol Pharmacol 1990; 38: 313–8PubMedGoogle Scholar
  65. 65.
    Ansher SS, Puri RK, Thompson WC, et al. The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice. Cancer Res 1992; 52: 262–6PubMedGoogle Scholar
  66. 66.
    Chen YL, Florentin I, Batt AM, et al. Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases. Biochem Pharmacol 1992; 44: 137–48PubMedCrossRefGoogle Scholar
  67. 67.
    Thal C, Kahwaji JE, Loeper J, et al. Administration of high doses of human recombinant interleukin-2 decreases the expression of several P-450 cytochromes in the rat. J Pharmacol Exp Ther 1994; 268: 515: 521PubMedGoogle Scholar
  68. 68.
    Chen YL, Le Vraux V, Leneveu A, et al. Acute phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649–60PubMedCrossRefGoogle Scholar
  69. 69.
    Gidal BE, Reiss WG, Liao JS, et al. Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics [letter]. Ann Pharmacother 1996; 30: 545–6PubMedGoogle Scholar
  70. 70.
    Niven RW, Whitcomb KL, Shaner L, et al. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 1995; 12: 1343–9PubMedCrossRefGoogle Scholar
  71. 71.
    Halme M, Maasilta P, Repo H, et al. Inhaled recombinant interferon-gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. Int J Radiat Oncol Biol Phys 1995; 31: 93–101PubMedCrossRefGoogle Scholar
  72. 72.
    Syed TA, Cheema KM, Kahlon BM, et al. Human leukocyte interferon-alpha in cream for treatment of genital herpes in Asian males: a placebo-controlled, double-blind study. Dermatology 1995; 191:32–5PubMedCrossRefGoogle Scholar
  73. 73.
    Schneider A, Grubert T, Kirchmayr R, et al. Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia. Arch Gynecol Obstet 1995; 256: 75–83PubMedCrossRefGoogle Scholar
  74. 74.
    Short SM, Rubas W, Paasch BD, et al. Transport of biologically active interferon-gamma across human skin in vitro. Pharm Res 1995; 12: 1140–5PubMedCrossRefGoogle Scholar
  75. 75.
    Maskin SL. Regression of limbal epithelial dysplasia with topical interferon. Arch Ophthalmol 1994; 112: 1145–6PubMedCrossRefGoogle Scholar
  76. 76.
    Takaya T, Ikeda C, Imagawa N, et al. Development of a colon delivery capsule and the pharmacological activity of recombinant human granulocyte colony-stimulating factor in beagle dogs. J Pharm Pharmacol 1995; 47: 474–8PubMedCrossRefGoogle Scholar
  77. 77.
    Lachman LB, Shih LC, Rao XM, et al. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses 1995; 11: 921–32PubMedCrossRefGoogle Scholar
  78. 78.
    Anderson PM, Hanson DC, Hasz DE, et al. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF, and interferon-gamma. Cytokine 1994; 6: 92–101PubMedCrossRefGoogle Scholar
  79. 79.
    Wood R, Montoya JG, Kundu SK, et al. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993; 167: 519–25PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Stephen C. Piscitelli
    • 1
  • William G. Reiss
    • 2
  • William D. Figg
    • 3
  • William P. Petros
    • 4
  1. 1.Clinical Pharmacokinetics Research Laboratory, Department of Pharmacy, Clinical CenterNational Institutes of HealthBethesdaUSA
  2. 2.Department of Pharmacy Practice and Science, School of PharmacyUniversity of MarylandBaltimoreUSA
  3. 3.Clinical Pharmacokinetics Section, Clinical Pharmacology Branch Division of Clinical SciencesNational Cancer InstituteBethesdaUSA
  4. 4.Clinical Pharmacology Laboratory, Bone Marrow Transplant ProgramDuke University Medical CenterDurhamUSA

Personalised recommendations